BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Conference call and webcast at 8:00 a.m. ET
NEW YORK, March 27, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, toda... Regenerative Medicine, Neurology, FDA BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2023 Category: Pharmaceuticals Source Type: news
FDA Panel Supports Tofersen for Rare Genetic ALS
(MedPage Today) -- A panel of FDA advisors voted unanimously that plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, is a reasonable surrogate endpoint in amyotrophic lateral sclerosis (ALS) associated with a mutation in... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 23, 2023 Category: American Health Source Type: news
Biogen ALS drug considered not effective by FDA advisory panel
Biogen Inc. BIIB, received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotrophic lateral sclerosis, or ALS, treatment did not show it was effective. On Wednesday, the FDA’s Peripheral and Central Nervous System Drugs…#biogeninc #als #fda #toferson #biogen (Source: Reuters: Health)
Source: Reuters: Health - March 23, 2023 Category: Consumer Health News Source Type: news
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease
The Food and Drug Administration's independent panel of advisors on Wednesday voted against the effectiveness of Biogen's investigational ALS drug for a rare and aggressive form of the disease. The drug tofersen was developed to treat a rare genetic form of amyotrophic lateral sclerosis, or ALS.…#biogen #als #lianaapostolova #michellemielke #fda #lougehrig #sod1 #nfl #sod1als #davidweisman (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2023 Category: Consumer Health News Source Type: news
FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease
The Food and Drug Administration's independent panel of advisors on Wednesday declined to endorse accelerated approval of Biogen's investigational ALS drug for a rare and aggressive form of the disease. The drug tofersen was developed to treat a rare genetic form of amyotrophic lateral sclerosis,…#biogen #als #lianaapostolova #michellemielke #fda #lougehrig #sod1 #nfl #sod1als #davidweisman (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2023 Category: Consumer Health News Source Type: news
Investigational ALS Drug May Have Clinical Benefit, FDA Staff Says
(MedPage Today) -- Tofersen, an investigational antisense drug developed to treat amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene (SOD1-ALS), may have clinical benefit, FDA reviewers indicated in briefing documents... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 21, 2023 Category: American Health Source Type: news
DNA treatment could delay paralysis that strikes nearly all patients with ALS
In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell. In turn, this triggers the loss of stathmin-2, a protein crucial to regeneration of neurons and the maintenance of their connections to muscle fibers, essential to contraction and movement. (Source: World Pharma News)
Source: World Pharma News - March 16, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Sanofi throws weight behind ALS startup in $88M round
A second Big Pharma firm has invested in a startup developing medicines for amyotrophic lateral sclerosis, or ALS. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 9, 2023 Category: American Health Authors: Rowan Walrath Source Type: news
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round
Financing supports clinical activities for Company's two lead programs in ALS and pipeline development
CAMBRIDGE, Mass., March 9, 2023 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Neurology, Venture Capital QurAlis , amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2023 Category: Pharmaceuticals Source Type: news
Bruce Willis Has Frontotemporal Dementia. Here ’ s What It Is
In an Instagram post, Bruce Willis’ family revealed that the actor has been diagnosed with frontotemporal dementia (FTD). The diagnosis comes nearly a year after his family revealed Willis has aphasia, which is characterized by difficulty speaking.
“Since we announced Bruce’s diagnosis of aphasia in spring 2022, Bruce’s condition has progressed and we now have a more specific diagnosis: frontotemporal dementia (known as FTD),” the family said in its statement, which was also posted on the Association for Frontotemporal Degeneration’s website.
Here’s what to know about the condition...
Source: TIME: Health - February 17, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Disease Explainer healthscienceclimate Source Type: news
Innovative ALS research fueled by $25 million from NIH
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2020/7/science-highlights/als/thumb894442.jpg?itok=sqWo-nyw" /><br /><p>New initiative encourages research to transform treatment and prevention of amyotrophic lateral sclerosis, a devastating disease.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Study links viral infections to Alzheimer ’s, Parkinson’s—with many caveats
A massive data mining study has found numerous associations between common viruses like the flu and devastating neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). The findings expand on previous research linking individual viruses to neurological diseases. But experts caution that the study, which relied on electronic medical records rather than biological samples, merely describes correlations and doesn’t prove causation.
Still, it’s “really exciting,” says Kristen Funk, a neuroimmunologist who studi...
Source: ScienceNOW - January 19, 2023 Category: Science Source Type: news
“Running Bitcoin” half marathon will commemorate Hal Finney
Fran Finney, the widow of early Bitcoin contributor Hal Finney, announced a charity half marathon in honor of her husband via Twitter on Dec. 27. The event is called “Running Bitcoin.” It aims to collect funds for research into treatment for ALS, or amyotrophic lateral sclerosis. Hal Finney was…#twitter #als #halfinney #satoshinakamoto #elonmusks #runningbitcoin #cryptoslate #franfinney (Source: Reuters: Health)
Source: Reuters: Health - December 28, 2022 Category: Consumer Health News Source Type: news
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
NEW YORK, Dec. 27, 2022 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administ... Regenerative Medicine, Neurology, FDA BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 27, 2022 Category: Pharmaceuticals Source Type: news
Analysis of accidental falls and the integration in the chronicity programs of patients with amyotrophic lateral sclerosis - Castro-Rodr íguez E, Azagra-Ledesma R, Gómez-Batiste Alertón X, Aguyé-Batista A, Zwart-Salmerón M, Cabanas-Valdés R, Caballero-Gómez FM, Clemente-Azagra C.
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disease. There is no curative treatment available, and these patients require multidisciplinary support to promote their comfort and quality of life. PAT... (Source: SafetyLit)
Source: SafetyLit - November 14, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
